实用医学杂志2012，Vol.28Issue(16)：2772-2774,3.DOI:10.3969/j.issn.1006-5725.2012.16.051
吡格列酮对2型糖尿病肾病患者骨桥蛋白和尿微量白蛋白的影响
Effects of pioglitazone on serum osteopontin and urinary microalbuminuria in type 2 diabetic patients with diabetic nephropathy
摘要
Abstract
Objective To investigate the effect of pioglitazone on serum OPN and UMA/Cr in type 2 diabetic patients with diabetic nephropathy. Methods Ninety type 2 diabetes patients were divided into two groups randomly according to UMA/Cr of Standards of Medical Care in Diabetes of 2009,diabetes mellitus (DM, UMA/Cr ＜ 30 μg/mg, n = 30) and diabetic nephropathy ( DN,UMA/Cr: 30-299μg/mg,n = 60). Meanwhile, thirty healthy cases were selected for the Normal control (NC,n = 30). Then DN were randomly divided into two groups; placebo group (placebo combined with Insulin therapy, n = 30) and pioglitazone group (Pioglitazone combined with Insulin therapy, n = 30). In all of the objectives, levels of glucose, lipid, renal function, CRP, OPN and UMA/Cr were examined and analyzed. Results After 3-month treatment, compared with placebo group, the levels of UMA/ Cr [ (35.02 ±6.38) vs (86.30 ± 12.21 )p.g/mg, P＜0.01], OPN [(394.24 ± 19.43) vs (457.00+ 15.21) ng/mL, P ＜ 0.01 ] and HbAlc , TG, CRP in pioglitazone group were significanct decreased, the difference was significance. In the pioglitazone group the levels of A UMA/Cr (△: the difference between before and after treatment) were correlated positively with AOPN (r = 0.673 ,P = 0.000). Conclusions The level of OPN is significant increase in type 2 diabetic patients with diabetic nephropathy Pioglitazone can reduce level of UMA/Cr, may be achieve partly by reduce the level of serum OPN.关键词
糖尿病肾病/骨桥蛋白/尿微量白蛋白/吡格列酮Key words
Diabetic nephropathy/ Osteopontin/ Urinary microalbuminuria/ Pioglitazone引用本文复制引用
张筠,王建平,臧丽,张世静..吡格列酮对2型糖尿病肾病患者骨桥蛋白和尿微量白蛋白的影响[J].实用医学杂志,2012,28(16):2772-2774,3.基金项目
湖南省高等学校科学研究项目(编号:09C844) （编号:09C844）
